Marthe Rigal

1.4k total citations
7 papers, 87 citations indexed

About

Marthe Rigal is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marthe Rigal has authored 7 papers receiving a total of 87 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 3 papers in Hematology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marthe Rigal's work include Acute Myeloid Leukemia Research (3 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Chronic Myeloid Leukemia Treatments (2 papers). Marthe Rigal is often cited by papers focused on Acute Myeloid Leukemia Research (3 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Chronic Myeloid Leukemia Treatments (2 papers). Marthe Rigal collaborates with scholars based in France, China and Vietnam. Marthe Rigal's co-authors include Claude Gardin, Sabine Bréchignac, Thorsten Braun, Christophe Lebœuf, Anne Janin, Bruno Quesnel, Benoît Caron, Xue Hou, Christophe Willekens and Sylvain Thépot and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Experimental & Clinical Cancer Research.

In The Last Decade

Marthe Rigal

6 papers receiving 85 citations

Peers

Marthe Rigal

HEMAT

MB

BE

BIOMA

GENET

Francesca Ferraro United States

Marco Sborgia Italy

Neeraj Sidharthan India

Karel Švojgr Czechia

Khoan Vu United States

Ana Marcos‐Jiménez Spain

Ethan Ellis United States

Alison Kennedy Australia

Dristhi Ragoonanan United States

Goda Choi Netherlands

Francesca Ferraro United States

Marthe Rigal

42 ×1.0

HEMAT

52 ×1.7

MB

14 ×0.6

BE

11 ×0.6

BIOMA

12 ×0.8

GENET

Citations per year, relative to Marthe Rigal Marthe Rigal (= 1×) peers Francesca Ferraro

Countries citing papers authored by Marthe Rigal

Since Specialization

Citations

This map shows the geographic impact of Marthe Rigal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marthe Rigal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marthe Rigal more than expected).

Fields of papers citing papers by Marthe Rigal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marthe Rigal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marthe Rigal. The network helps show where Marthe Rigal may publish in the future.

Co-authorship network of co-authors of Marthe Rigal

This figure shows the co-authorship network connecting the top 25 collaborators of Marthe Rigal. A scholar is included among the top collaborators of Marthe Rigal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marthe Rigal. Marthe Rigal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Lévi, Françis, Zhe Huang, Abdoulaye Karaboué, et al.. (2025). Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: A bicentric bicontinental study.. Journal of Clinical Oncology. 43(16_suppl). 2510–2510.

2.

Rahmé, Ramy, Valérie Vidal, Thomas Hueso, et al.. (2023). Treatment of Adverse-Risk and Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients with FLAG-IDA ± Venetoclax and CLAG-M: A Monocentric Experience. Blood. 142(Supplement 1). 1520–1520. 2 indexed citations

3.

Rigal, Marthe, Kader Chouahnia, A. Paix, et al.. (2020). Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer. Vaccines. 8(4). 730–730. 9 indexed citations

4.

Pons, Thomas, Xue Hou, Khanh Do, et al.. (2019). Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer. Journal of Experimental & Clinical Cancer Research. 38(1). 306–306. 30 indexed citations

5.

Nguyen, Thuy Thanh, Quang Nguyen, Céline Desvignes, et al.. (2019). A successful compartmental approach for the treatment of breast cancer brain metastases. Cancer Chemotherapy and Pharmacology. 83(3). 573–580. 2 indexed citations

6.

Harel, Stéphanie, Céline Berthon, Christophe Willekens, et al.. (2015). Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leukemia Research. 39(5). 501–504. 38 indexed citations

7.

Braun, Thorsten, Céline Berthon, Christophe Willekens, et al.. (2013). Treatment With Decitabine (DAC) After Azacitidine (AZA) Failure In High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML). Blood. 122(21). 2796–2796. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact